sur PolyPeptide Group
PolyPeptide Group Observes Market Speculation Regarding Potential Takeover
PolyPeptide Group AG, a global CDMO specializing in peptide-based pharmaceutical ingredients, has noted recent market rumors suggesting potential takeover interest from investors. The company, headquartered in Baar, Switzerland, announced its policy to refrain from commenting on such speculations.
The Board of Directors, in collaboration with Draupnir Holding B.V., PolyPeptide's majority shareholder, is reviewing strategic options. This review is still in its early stages, and no decisions have been made regarding potential transactions or outcomes. The company emphasizes its commitment to enhancing long-term value for stakeholders, aiming to double its 2023 revenue by 2028.
With strong growth prospects, PolyPeptide remains focused on executing its strategic plan to deliver sustainable value.
R. E.
Copyright © 2026 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de PolyPeptide Group